Volume 18, Number 4—April 2012
Letter
Leishmania Resistance to Miltefosine Associated with Genetic Marker
Table
Isolate | Year | AmpB | Miltefosine | IC50, µmol/L ± SEM |
Ldmt SNP | ||||
---|---|---|---|---|---|---|---|---|---|
AmpB |
Miltefosine |
||||||||
Promastigotes | Axenic amastigotes | Promastigotes | Axenic amastigotes | ||||||
– | 1998 | 3 mg/kg/d × 5 d; then 1×/wk × 5 wk | – | – | – | – | – | – | |
S1 | 2000 | 3 mg/kg/d × 5 d; then 1×/wk × 5 wk | – | 0.09 ± 0.04† | 0.10 ± 0.03 | 7.14 ± 0.56† | 5.00± ± 0.7† | L832 | |
– | 2001 | 4 mg/kg/d × 5 d; then 1×/wk × 5 wk | 50 mg 2×/d | – | – | – | – | – | |
S3 | 2005 | 4 mg/kg/d × 5 d; then 1×/wk × 5 wk‡ | 0.13 ± 0.03 | 0.20 ± 0.03 | 25.93 ± 1.46† | 21.00 ± 1.50† | 832L/F | ||
S4 | 0.24 ± 0.01† | 0.15 ± 0.02 | 27.89 ± 1.76† | 31.90 ± 1.60† | |||||
– | 2007 | 4 mg/kg/d × 5 d; then 1×/wk × 5 wk | – | – | – | – | – | ||
S6 | 2008 | 4 mg/kg/d × 5 d; then 1×/wk × 5 wk | – | 0.16 ± 0.03 | 0.11 ± 0.03 | 44.30 ± 3.70† | 50.10 ± 1.00† | 832F | |
S7 | 2010 | 4 mg/kg/d × 5 d; then 1×/wk × 5 wk | – | – | – | – | – | L832 | |
Reference strain | |||||||||
LV9 WT | 0.03 ± 0.02 | 0.02 ± 0.05 | 4.46 ± 0.29† | 6.20 ± 0.3 | L832 | ||||
LV9 Miltefosine-R | 0.22 ± 0.04 | 0.70 ± 0.09 | 45.84 ± 2.40† | 54.20 ± 2.20† | 832F | ||||
DD8 WT | 0.06 ± 0.02† | 0.05 ± 0.03† | 17.40 ± 1.70 | 12.40 ± 1.50 | L832 | ||||
DD8 AmpB-R | 1.42 ± 0.06† | 1.00 ± 0.07† | 15.20 ± 1.00 | 10.30 ± 1.20 | L832 |
*IC50, 50% inhibitory concentration; AmpB, amphotericin B; Ldmt, Leishmania donovani miltefosine transporter gene; SNP, single-nucleotide polymorphism; –, assay not performed because sample unavailable or not culturable; WT, wild type; R, resistant.
†Significance was analyzed by using the nonparametric Mann-Whitney U test to compare the IC50 of the isolates with the IC50 of reference strains; p<0.01 was considered significant. IC50 of AmpB and miltefosine was compared with IC50 of reference strains and S1/S3, S1/S4, and S1/S6. Miltefosine: S1/S3, S1/S4, S1/S6, S4/S6; p<0.01. AmpB: S1/S4 significant p<0.01; S1/S3, S1/S6 not significant.
‡For each relapse.
Page created: March 16, 2012
Page updated: March 16, 2012
Page reviewed: March 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.